ArticleFrontiers in public health2025
Cost-effectiveness analysis of tuberculosis screening in diabetic patients in China: a decision-analytic Markov model.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Commentary: RecombinantFrontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To establish a pharmacoeconomic model to evaluate the cost-effectiveness of various screening strategies for latent tuberculosis infection (LTBI) in older diabetic patients and provide evidence for health policy formulation. Methods: A decision tree-Markov model was constructed to simulate the LTBI screening process for 10,000 diabetic patients aged 60 years and older, analyzing the costs and health utilities of different screening strategies. Results: The incremental cost-effectiveness ratio (ICER) of the traditional tuberculin skin test (TST) strategy was significantly lower than the willingness-to-pay threshold, indicating its economic advantage. Meanwhile, the economic benefit of the new recombinant tuberculosis fusion protein skin test (C-TST) compared to TST was not significant, and the interferon-gamma release assay (IGRA) was considered the least cost-effective option due to its high cost. One-way sensitivity analysis identified key parameters that affect the economic viability of screening strategies, such as non-tuberculous mortality rates by age group, LTBI mortality rates, and annual medical costs associated with diabetes. When the non-tuberculous mortality rate reached a certain threshold, the economic viability of all screening strategies was impacted. Additionally, probabilistic sensitivity analysis indicated that TST had a high probability (70%) of being the most cost-effective screening option at a common willingness-to-pay threshold. Conclusion: Screening for LTBI in older diabetic patients is a cost-effective approach. The strategy should take into account economic conditions and healthcare resource allocation in various regions to enhance the effectiveness of public health interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.